Apogee Therapeutics (APGE) – Investment Analysts’ Recent Ratings Updates

Apogee Therapeutics (NASDAQ: APGE) has recently received a number of price target changes and ratings updates:

• 6/23/2026 – Apogee Therapeutics was downgraded by TD Cowen to “hold”.
• 6/23/2026 – Apogee Therapeutics was downgraded by Guggenheim from “buy” to “neutral”.
• 6/23/2026 – Apogee Therapeutics was downgraded by UBS Group AG from “buy” to “neutral”. They now have a $135.11 price target on the stock, up from $100.00.
• 6/23/2026 – Apogee Therapeutics had its “neutral” rating reaffirmed by Citigroup Inc.. They now have a $135.00 price target on the stock, up from $125.00.
• 6/22/2026 – Apogee Therapeutics was downgraded by Deutsche Bank Aktiengesellschaft from “buy” to “hold”. They now have a $135.00 price target on the stock, up from $116.00.
• 6/22/2026 – Apogee Therapeutics was given a new $135.11 price target by Craig Hallum. They now have a “hold” rating on the stock.
• 6/22/2026 – Apogee Therapeutics was downgraded by Wedbush from “outperform” to “neutral”. They now have a $135.00 price target on the stock.
• 6/22/2026 – Apogee Therapeutics was downgraded by Citigroup Inc. from “strong-buy” to “hold”.
• 6/22/2026 – Apogee Therapeutics was downgraded by Canaccord Genuity Group Inc. from “buy” to “hold”. They now have a $135.11 price target on the stock, up from $130.00.
• 6/8/2026 – Apogee Therapeutics had its price target raised by Royal Bank Of Canada from $82.00 to $97.00. They now have a “sector perform” rating on the stock.
• 5/28/2026 – Apogee Therapeutics was given a new $89.00 price target by The Goldman Sachs Group, Inc..
• 5/28/2026 – Apogee Therapeutics was upgraded by The Goldman Sachs Group, Inc. to “hold”.
• 5/27/2026 – Apogee Therapeutics had its price target lowered by Truist Financial Corporation from $83.00 to $81.00. They now have a “hold” rating on the stock.
• 5/27/2026 – Apogee Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $137.00 price target on the stock.
• 5/27/2026 – Apogee Therapeutics had its price target raised by Wedbush from $120.00 to $135.00. They now have an “outperform” rating on the stock.
• 5/1/2026 – Apogee Therapeutics is now covered by Rothschild & Co Redburn. They set a “buy” rating and a $140.00 price target on the stock.
• 5/1/2026 – Apogee Therapeutics is now covered by Rothschild & Co Redburn. They set a “buy” rating and a $140.00 price target on the stock.

Insider Activity

In other Apogee Therapeutics news, insider Carl Dambkowski sold 5,500 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $78.71, for a total value of $432,905.00. Following the sale, the insider owned 205,648 shares in the company, valued at $16,186,554.08. This represents a 2.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Thomas Henderson sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $83.38, for a total value of $1,667,600.00. Following the completion of the sale, the chief executive officer directly owned 1,095,987 shares of the company’s stock, valued at approximately $91,383,396.06. The trade was a 1.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 76,500 shares of company stock valued at $6,323,295 over the last quarter. 24.30% of the stock is currently owned by company insiders.

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.